Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria

    ... with reduced survival. The terminal complement inhibitor eculizumab is proven to be effective and safe in adults and approved by the ... and safety in seven children with PNH 11-17 years of age. Eculizumab was intravenously administered at 600 mg weekly for 4 weeks, ...

    Research Article last updated 05/22/2014 - 8:29am.

  2. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.

    ... the safety and efficacy of the complement inhibitor eculizumab in altering its progression. Renal dysfunction or damage was ... rate [GFR] <or=60 ml/min/1.73 m(2); Stage 3, 4, or 5). Eculizumab treatment was safe and well-tolerated in patients with renal ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Successful Use of Eculizumab in a Pediatric Patient Treated for Paroxysmal Nocturnal Hemoglobinuria

    ... in adulthood and are very rarely reported in children. Eculizumab , a humanized monoclonal antibody targeting and ... disease-related complications in patients with PNH. Although eculizumab is not licensed for use in pediatrics, we report a young PNH patient ...

    Research Article last updated 07/31/2012 - 12:38pm.

  4. Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab

    ... under treatment with the anti-complement antibody eculizumab who developed pancytopenia , requiring blood ...

    Research Article last updated 01/08/2014 - 9:53am.

  5. Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab.

    ... an increased rate of premature labor and fetal loss. Eculizumab , a humanized monoclonal antibody directed against the terminal ... has revolutionized treatment of PNH. However, the role of eculizumab in pregnancy is unclear. We review the current strategies for the ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience

    ... 27 years at pregnancy. None of these women had received eculizumab during their pregnancy. Maternal complications, consisting ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Eculizumab treatment improved renal hemosiderosis in a patient with paroxysmal nocturnal hemoglobinuria

    Journal Title:  Int J Hematol Primary Author:  Iki S Author(s):  Iki S, Ohgi ...

    Research Article last updated 12/09/2016 - 2:06pm.

  8. Safety and Effect of GL-ONC1 Administered IV With or Without Eculizumab Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery

    ... product, GL-ONC1, alone or in combination with eculizumab . This study aims to find the highest dose of GL-ONC1 that can be given alone, or with eculizumab, without causing unacceptable side effects. GL-ONC1 is considered ...

    Clinical Trial last updated 04/28/2016 - 1:57pm.

  9. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria

    ... The targeted terminal complement inhibitor eculizumab (Soliris) reduces intravascular hemolysis in patients ... reducing the requirement for packed red cell transfusions. Eculizumab is generally well tolerated in patients with PNH, although the risk ...

    Research Article last updated 07/30/2012 - 2:23pm.

  10. Assessment of Human Antihuman Antibodies to Eculizumab After Long-Term Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria

    Journal Title:  Am J Hematol Primary Author:  Hillmen P Author(s):  Hillmen P...

    Research Article last updated 04/29/2016 - 10:20am.